Free Trial
TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Medicenna Therapeutics logo
C$1.50 -0.12 (-7.41%)
(As of 11/20/2024 ET)

About Medicenna Therapeutics Stock (TSE:MDNA)

Key Stats

Today's Range
C$1.48
C$1.64
50-Day Range
C$1.45
C$2.51
52-Week Range
C$0.38
C$2.98
Volume
38,304 shs
Average Volume
107,149 shs
Market Capitalization
C$114.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Medicenna Reports Promising Results with MDNA11
See More Headlines

MDNA Stock Analysis - Frequently Asked Questions

Medicenna Therapeutics' stock was trading at C$0.42 at the start of the year. Since then, MDNA stock has increased by 257.1% and is now trading at C$1.50.
View the best growth stocks for 2024 here
.

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
C$-26,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$1.31 per share
Book Value
C$0.30 per share

Miscellaneous

Free Float
N/A
Market Cap
C$114.65 million
Optionable
Not Optionable
Beta
1.21
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (TSE:MDNA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners